---
title: "Transcriptomic Features Add Predictive Value for Immunotherapy Response in Advanced Urothelial Car"
id: "medrxiv-6-incremental-predictive-value-and-representation-of-transcriptomic-features-for"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-6-incremental-predictive-value-and-representation-of-transcriptomic-features-for"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.14.26363060v1?rss=1"
published_at: "2026-09-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Transcriptomic Features Add Predictive Value for Immunotherapy Response in Advanced Urothelial Car
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-6-incremental-predictive-value-and-representation-of-transcriptomic-features-for
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.14.26363060v1?rss=1)
- **Published At:** 2026-09-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study assessed whether **transcriptomic** representations add predictive value for immunotherapy response in advanced urothelial carcinoma beyond clinical variables and established tumor biomarkers. - Analysis used 298 patients from the IMvigor210 trial of **atezolizumab** (a PD-L1 inhibitor) and compared knowledge-guided tumor microenvironment gene-set features to data-driven, transcriptome-wide gene selection. - Knowledge-guided features increased **AUPRC** by 0.058 over clinical variables alone, and provided smaller incremental gains after adding standard biomarkers: +0.011 when tumor mutational burden (**TMB**) and **PD-L1** were included, and +0.016 when research-enriched biomarkers (neoantigen burden, immune phenotype) were added. - Data-driven gene selection was unstable across cross-validation folds (mean Jaccard similarity 0.227) and under the clinical-plus-biomarker baseline produced an **AUPRC** 0.150 lower than the knowledge-guided representation. - Despite instability in gene selection, IL-6/JAK/STAT3 signaling emerged as the most recurrent Hallmark pathway, indicating pathway-level convergence across data-driven results. - External validation in cohort GSE176307 showed a similar pattern: knowledge-guided features improved AUPRC by 0.128 over clinical variables and by 0.019 over the clinical-plus-biomarker baseline. - The authors conclude that biologically informed transcriptomic representations are preferable when molecular profiling adds predictive value beyond established biomarkers. - All data used were publicly available (IMvigor210CoreBiologies and GSE176307); the authors reported no competing interests and followed ethical guidelines.
## Clinical Analysis & Structured Key Points
Incremental Predictive Value and Representation of Transcriptomic Features for Immunotherapy Response in Advanced Urothelial Carcinoma | medRxiv Skip to main content Incremental Predictive Value and Representation of Transcriptomic Features for Immunotherapy Response in Advanced Urothelial Carcinoma Grace Y Han , Hansen Tai , Fusheng Wang doi: https://doi.org/10.64898/2026.09.14.26363060 Grace Y Han 1 Renaissance School of Medicine at Stony Brook University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hansen Tai 2 Mather Hospital at Northwell Health; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Fusheng Wang 3 Stony Brook University Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: fusheng.wang{at}stonybrook.edu Abstract Info/History Metrics Data/Code Preview PDF Abstract Transcriptomic profiling may improve immunotherapy response prediction, but its incremental value beyond established clinical and tumor biomarkers is unclear. In 298 patients with advanced urothelial carcinoma from IMvigor210, an atezolizumab (PD-L1 inhibitor) trial, we compared knowledge-guided tumor microenvironment gene-set features with data-driven transcriptome-wide gene selection. Knowledge-guided features improved AUPRC by 0.058 beyond clinical variables alone, with smaller gains after including standard biomarkers (TMB, PD-L1; +0.011) and research-enriched biomarkers (neoantigen burden, immune phenotype; +0.016). Data-driven gene selection was unstable across folds (mean Jaccard similarity, 0.227) and, under the clinical-plus-biomarker baseline, yielded an AUPRC 0.150 lower than the knowledge-guided representation. Despite this instability, IL-6/JAK/STAT3 signaling was the most recurrent Hallmark pathway, suggesting pathway-level biological convergence. External evaluation showed a similar pattern: knowledge-guided features improved AUPRC by 0.128 over clinical variables vs. 0.019 over clinical-plus-biomarker baseline. These findings support biologically informed transcriptomic representation when molecular profiling adds value beyond established biomarkers. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study used ONLY de-identified, publicly available human data. IMvigor210 data were obtained from the publicly available IMvigor210CoreBiologies resource (http://research-pub.gene.com/IMvigor210CoreBiologies/), and the external validation cohort GSE176307 was obtained from the NCBI Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE176307). No controlled-access or application-based datasets were used. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present work are contained in the manuscript. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Posted September 21, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Incremental Predictive Value and Representation of Transcriptomic Features for Immunotherapy Response in Advanced Urothelial Carcinoma Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Incremental Predictive Value and Representation of Transcriptomic Features for Immunotherapy Response in Advanced Urothelial Carcinoma Grace Y Han , Hansen Tai , Fusheng Wang medRxiv 2026.09.14.26363060; doi: https://doi.org/10.64898/2026.09.14.26363060 Share This Article: Copy Citation Tools Incremental Predictive Value and Representation of Transcriptomic Features for Immunotherapy Response in Advanced Urothelial Carcinoma Grace Y Han , Hansen Tai , Fusheng Wang medRxiv 2026.09.14.26363060; doi: https://doi.org/10.64898/2026.09.14.26363060 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (619) Allergy and Immunology (903) Anesthesia (335) Cardiovascular Medicine (4832) Dentistry and Oral Medicine (479) Dermatology (419) Emergency Medicine (651) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1633) Epidemiology (15980) Forensic Medicine (33) Gastroenterology (1206) Genetic and Genomic Medicine (7067) Geriatric Medicine (734) Health Economics (1067) Health Informatics (5061) Health Policy (1438) Health Systems and Quality Improvement (1776) Hematology (587) HIV/AIDS (1347) Infectious Diseases (except HIV/AIDS) (16310) Intensive Care and Critical Care Medicine (1176) Medical Education (671) Medical Ethics (155) Nephrology (727) Neurology (7294) Nursing (369) Nutrition (1084) Obstetrics and Gynecology (1244) Occupational and Environmental Health (1006) Oncology (3617) Ophthalmology (1055) Orthopedics (398) Otolaryngology (458) Pain Medicine (474) Palliative Medicine (140) Pathology (709) Pediatrics (1805) Pharmacology and Therapeutics (739) Primary Care Research (769) Psychiatry and Clinical Psychology (5921) Public and Global Health (9772) Radiology and Imaging (2433) Rehabilitation Medicine and Physical Therapy (1456) Respiratory Medicine (1250) Rheumatology (643) Sexual and Reproductive Health (773) Sports Medicine (581) Surgery (783) Toxicology (107) Transplantation (305) Urology (293)
## Related Clinical Research

- [Urine cfDNA methylation distinguishes non‑muscle invasive bladder cancer: pilot cfMeDIP‑seq study](https://medichelpline.com/clinical-feed/medrxiv-22-urine-dna-methylation-as-a-potential-diagnostic-and-surveillance-tool-in-non.md)
- [Causal Multi‑modal AI (CTX) Stratifies Residual Risk and Predicts Everolimus Benefit in Node‑Posit](https://medichelpline.com/clinical-feed/medrxiv-5-a-causal-multi-modal-ai-model-stratifies-residual-risk-and-identifies.md)
- [Structured aerobic exercise linked to lower cancer recurrence and improved survival](https://medichelpline.com/clinical-feed/medical-news-today-0-aerobic-exercise-could-help-improve-outlook-after-cancer-treatment.md)
- [Inflammatory Biomarkers and Risk of Postmenopausal ER-Positive Breast Cancer](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-inflammatory-biomarkers-and-risk-of-postmenopausal-oestrogen-receptor-positive.md)
- [Educating Patients on ‘Asian Glow’ and Alcohol Risks in East Asian Populations](https://medichelpline.com/clinical-feed/stat-news-0-opinion-doctors-should-educate-patients-about-asian-glow-and-drinking-risks.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.